Autolus Therapeutics (AUTL) Projected to Release Earnings on Tuesday

Autolus Therapeutics (NASDAQ:AUTL) is expected to be posting its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Autolus Therapeutics to post earnings of ($0.21) per share and revenue of $39.54 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The business had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. On average, analysts expect Autolus Therapeutics to post ($0.76) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.

Autolus Therapeutics Price Performance

Shares of AUTL traded down $0.01 during midday trading on Tuesday, hitting $1.42. 1,740,011 shares of the company traded hands, compared to its average volume of 1,803,574. The stock has a market cap of $376.62 million, a price-to-earnings ratio of -1.33 and a beta of 2.15. The firm has a 50 day moving average of $1.89 and a 200-day moving average of $1.67. The company has a debt-to-equity ratio of 1.04, a quick ratio of 4.40 and a current ratio of 4.89. Autolus Therapeutics has a 52 week low of $1.18 and a 52 week high of $2.58.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. HC Wainwright began coverage on Autolus Therapeutics in a report on Monday. They set a “buy” rating for the company. Finally, Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.